Fundamental studies of therapies that target the CD26 molecule as a treatment in kidney disease

• Project/Area Number: 24659419
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Kidney internal medicine
• Research Institution: Jikei University School of Medicine
• Principal Investigator: KOBAYASHI Seiji 東京慈恵会医科大学, 医学部, 助教 (80408400)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: CD26 / 難治性糸球体腎炎 / バイオマーカー / CD26DPPⅣ / ＣＤ２６ＤＰＰIV / CD26DPPIV

Outline of Final Research Achievements

CD26 is a T-cell activation antigen that contains dipeptidyl peptidase IV (DPPⅣ) activity and binds adenosine deaminase. We examined serum soluble CD26 levels and CD26 DPPⅣ activity in patients with CKD. We have demonstrated that soluble CD26 and CD26 DPPⅣ activity in the serum does not depend on renal function. We also investigated that soluble CD26 levels and CD26 DPPⅣactivity in the serum of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. We showed that soluble CD26 levels and CD26DPPⅣ activity in the serum exhibited significantly negative correlation of DAS-28ESR and DAS-28CRP. Our results suggest that Soluble CD26 is a one of the biomarkers in inflammatory diseases that is not dependent on renal function.

Research Products

• [Presentation] 腎機能障害が血清可溶性CD26及びCD26DPPIV活性比に及ぼす影響の検討 (2012)
  • Author(s): 小林 政司
  • Organizer: 第55回日本腎臓学会学術総会
  • Place of Presentation: 横浜